Hypervitaminoza D - Management
Immediately discontinue all vitamin D supplementation, initiate aggressive intravenous hydration with normal saline, and administer loop diuretics to promote calciuresis; add corticosteroids (prednisone) if hypercalcemia persists despite initial measures.
Clinical Recognition
Hypervitaminosis D presents with symptoms of hypercalcemia including:
- Confusion, apathy, altered mental status
- Recurrent vomiting and abdominal pain
- Polyuria, polydipsia, and dehydration
- Acute kidney injury 1, 2
The hallmark laboratory finding is serum 25(OH)D concentration >150 ng/ml (375 nmol/L) accompanied by hypercalcemia 2.
Immediate Management Algorithm
Step 1: Stop All Vitamin D Sources
- Discontinue all vitamin D supplementation immediately 1, 3
- Review all medications and over-the-counter supplements
- Verify actual doses taken (dispensing errors can result in patients receiving 50,000 IU daily instead of intended 1,000 IU) 3
Step 2: Treat Hypercalcemia Aggressively
- Intravenous hydration with normal saline to restore volume and promote renal calcium excretion 1
- Loop diuretics (furosemide) to enhance calciuresis once adequate hydration is achieved 1
- Corticosteroids (prednisone) if hypercalcemia persists - particularly effective as they reduce intestinal calcium absorption and oppose vitamin D effects 1
Step 3: Monitor and Support
- Serial monitoring of:
- Serum calcium levels
- Renal function (creatinine, BUN)
- Serum 25(OH)D concentrations 4
- Supportive care for acute kidney injury if present
Expected Recovery Timeline
Recovery is typically slow but complete with appropriate management. In documented cases, serum calcium, vitamin D concentrations, and renal function returned to baseline within 5 months after discontinuation and treatment 3. Clinical and biochemical improvement should be evident within days to weeks of initiating therapy 1.
Special Populations at Risk
Patients with Granulomatous Disorders
Patients with sarcoidosis, tuberculosis, chronic fungal infections, or lymphomas have activated macrophages producing 1,25(OH)₂D in an unregulated fashion, causing hypercalciuria and hypercalcemia even at 25(OH)D levels >30 ng/ml 4. These patients require:
- Target 25(OH)D levels of only 20-30 ng/ml (lower than general population)
- Careful serial monitoring of both 25(OH)D and calcium levels 4
Pediatric Considerations
- Children with Williams syndrome or other conditions predisposing to hypercalcemia require special caution 4
- Breastfed infants receiving overzealous supplementation are at risk 5
Critical Pitfalls to Avoid
Dosing conversion errors are a major cause of iatrogenic hypervitaminosis D. The difference between 1,000 IU daily (standard supplementation) and 50,000 IU daily (treatment dose for deficiency) is 50-fold 3, 6. Electronic prescribing systems should flag such discrepancies.
Self-medication with mega-doses is increasingly common as patients become aware of vitamin D benefits without understanding toxicity risks 1, 6. Patient education is essential.
Failure to monitor during high-dose therapy: Even prescribed high-dose regimens (6,000-10,000 IU/d for obesity or malabsorption) require monitoring to prevent toxicity 4.
Prevention Context
While the guidelines provided focus on treating deficiency 4, they emphasize that maintenance doses of 50,000 IU every other week were used "without any untoward toxicity" in controlled settings 4. However, daily ingestion of 50,000 IU represents gross overdosing and will cause toxicity within months 3.
The key distinction: therapeutic high doses must be time-limited (8 weeks for 50,000 IU weekly), followed by appropriate maintenance dosing (1,500-2,000 IU/d for general population, 3,000-6,000 IU/d for high-risk groups) 4.